Emerging drugs for essential thrombocythemia

被引:2
作者
Masarova, Lucia [1 ]
Verstovsek, Srdan [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
关键词
Essential thrombocytopenia; interferon; JAK2; inhibitors; myeloproliferative neoplasms; novel therapies; CHRONIC MYELOPROLIFERATIVE DISORDERS; PEGYLATED INTERFERON ALPHA-2A; POLYCYTHEMIA-VERA; OPEN-LABEL; HEMATOLOGIC CONTROL; MYELOID METAPLASIA; ANAGRELIDE ALLOWS; POOR TOLERANCE; HYDROXYUREA; JAK2;
D O I
10.1080/14728214.2019.1615437
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic management of this disease has remained largely unchanged in the past decades. Treatment has mostly focused on decreasing the risk of complications, especially prevention of thrombotic or hemorrhagic events. Areas covered: Over recent years, the treatment options of ET have been expanding with some novel agents on the horizon. The classes of agents described in this review include targeted and immunomodulatory agents, such as JAK1/2 inhibitors, interferon-alpha, histone deacetylase inhibitors, telomerase inhibitors and human double minute 2 inhibitors. These compounds entered various stages of development, albeit the only portion of them is currently actively undergoing evaluation in clinical trials. In this review, we look at the current therapies and discuss novel agents available in the management of ET. Expert opinion: The drug development in ET possesses several challenges stemming from its relatively benign and prolonged disease course. Therapy focused on reducing the risk of thrombotic and hemorrhagic complications and symptom management needs to be chosen wisely as a vast majority of these patients have a near-normal life expectancy. To date, no therapy has shown effective and definitive alteration of the disease behavior. Although novel agents are in development and hopefully some of them will extend treatment armamentarium of ET, their exact role remains to be determined.
引用
收藏
页码:93 / 105
页数:13
相关论文
共 90 条
[1]  
Ahn INE, 2011, BLOOD, V118, P517
[2]   Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation [J].
Alvarez-Larran, Alberto ;
Pereira, Arturo ;
Guglielmelli, Paola ;
Carlos Hernandez-Boluda, Juan ;
Arellano-Rodrigo, Eduardo ;
Ferrer-Marin, Francisca ;
Samah, Alimam ;
Griesshammer, Martin ;
Kerguelen, Ana ;
Andreasson, Bjorn ;
Burgaleta, Carmen ;
Schwarz, Jiri ;
Garcia-Gutierrez, Valentin ;
Ayala, Rosa ;
Barba, Pere ;
Teresa Gomez-Casares, Maria ;
Paoli, Chiara ;
Drexler, Beatrice ;
Zweegman, Sonja ;
McMullin, Mary F. ;
Samuelsson, Jan ;
Harrison, Claire ;
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Besses, Carlos .
HAEMATOLOGICA, 2016, 101 (08) :926-931
[3]   A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia [J].
Andersen, Christen L. ;
McMullin, Mary F. ;
Ejerblad, Elisabeth ;
Zweegman, Sonja ;
Harrison, Claire ;
Fernandes, Savio ;
Bareford, David ;
Knapper, Steven ;
Samuelsson, Jan ;
Loefvenberg, Eva ;
Linder, Olle ;
Andreasson, Bjorn ;
Ahlstrand, Erik ;
Jensen, Morten K. ;
Bjerrum, Ole W. ;
Vestergaard, Hanne ;
Larsen, Herdis ;
Klausen, Tobias W. ;
Mourits-Andersen, Torben ;
Hasselbalch, Hans C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (04) :498-508
[4]  
[Anonymous], 1967, JAMA, V200, P619
[5]   Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN [J].
Antonioli, Elisabetta ;
Guglielmelli, Paola ;
Pieri, Lisa ;
Finazzi, MariaChiara ;
Rumi, Elisa ;
Martinelli, Vincenzo ;
Vianelli, Nicola ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
De Stefano, Valerio ;
Za, Tommaso ;
Rossi, Elena ;
Ruggeri, Marco ;
Elli, Elena ;
Cacciola, Rossella ;
Cacciola, Emma ;
Pogliani, Enrico ;
Rodeghiero, Francesco ;
Baccarani, Michele ;
Passamonti, Francesco ;
Finazzi, Guido ;
Rambaldi, Alessandro ;
Bosi, Alberto ;
Cazzola, Mario ;
Barbui, Tiziano ;
Vannucchi, Alessandro M. .
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (05) :552-554
[6]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[7]   Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia [J].
Baerlocher, Gabriela M. ;
Leibundgut, Elisabeth Oppliger ;
Ottmann, Oliver G. ;
Spitzer, Gary ;
Odenike, Olatoyosi ;
McDevitt, Michael A. ;
Roth, Alexander ;
Daskalakis, Michael ;
Burington, Bart ;
Stuart, Monic ;
Snyder, David S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (10) :920-928
[8]   Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia [J].
Barbui, T. ;
Vannucchi, A. M. ;
Buxhofer-Ausch, V. ;
De Stefano, V. ;
Betti, S. ;
Rambaldi, A. ;
Rumi, E. ;
Ruggeri, M. ;
Rodeghiero, F. ;
Randi, M. L. ;
Bertozzi, I. ;
Gisslinger, H. ;
Finazzi, G. ;
Carobbio, A. ;
Thiele, J. ;
Passamonti, F. ;
Falcone, C. ;
Tefferi, A. .
BLOOD CANCER JOURNAL, 2015, 5 :e369-e369
[9]   Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms [J].
Barbui, Tiziano ;
Ghirardi, Arianna ;
Masciulli, Arianna ;
Carobbio, Alessandra ;
Palandri, Francesca ;
Vianelli, Nicola ;
De Stefano, Valerio ;
Betti, Silvia ;
Di Veroli, Ambra ;
Iurlo, Alessandra ;
Cattaneo, Daniele ;
Delaini, Federica ;
Bonifacio, Massimiliano ;
Scaffidi, Luigi ;
Patriarca, Andrea ;
Rumi, Elisa ;
Stephenson, Clemency ;
Guglielmelli, Paola ;
Elli, Elena Maria ;
Miroslava, Palova ;
Bertolotti, Laura ;
Erez, Daniel ;
Gomez, Montse ;
Wille, Kai ;
Perez-Encinas, Manuel ;
Lunghi, Francesca ;
Figueras, Anna Angola ;
Fox, Maria Laura ;
Beggiato, Eloise ;
Benevolo, Giulia ;
Carli, Giuseppe ;
Cacciola, Rossella Rosari ;
McMullin, Mary Frances ;
Tieghi, Alessia ;
Flores, Valle Recanses ;
Marchetti, Monia ;
Griesshammer, Martin ;
Alvarez-Larran, Alberto ;
Vannucchi, Alessandro M. ;
Finazzi, Guido .
BLOOD, 2018, 132
[10]   A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group [J].
Barosi, G. ;
Besses, C. ;
Birgegard, G. ;
Briere, J. ;
Cervantes, F. ;
Finazzi, G. ;
Gisslinger, H. ;
Griesshammer, M. ;
Gugliotta, L. ;
Harrison, C. ;
Hasselbalch, H. ;
Lengfelder, E. ;
Reilly, J. T. ;
Michiels, J. J. ;
Barbui, T. .
LEUKEMIA, 2007, 21 (02) :277-280